반응식
[CH3:1][C:2]1[C:6]([CH2:7][O:8][C:9]2[CH:14]=[CH:13][C:12]([S:15]([NH:18][C:19]3[CH:24]=[CH:23][C:22]([CH:25]([CH3:27])[CH3:26])=[CH:21][N:20]=3)(=[O:17])=[O:16])=[CH:11][CH:10]=2)=[C:5]([CH3:28])[O:4][N:3]=1.[C:29](N=C(N(C)C)N(C)C)([CH3:32])([CH3:31])[CH3:30]>C(#N)C>[CH3:1][C:2]1[C:6]([CH2:7][O:8][C:9]2[CH:10]=[CH:11][C:12]([S:15]([N:18]([CH2:30][CH:29]([CH3:32])[CH3:31])[C:19]3[CH:24]=[CH:23][C:22]([CH:25]([CH3:26])[CH3:27])=[CH:21][N:20]=3)(=[O:17])=[O:16])=[CH:13][CH:14]=2)=[C:5]([CH3:28])[O:4][N:3]=1참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
The title compound (7.6 mg) was prepared from 4-((3,5-dimethylisoxazol-4-yl)methoxy)-N-(5-isopropylpyridin-2-yl)benzenesulfonamide (39 mg, 0.097 mmol) and 2-(tert-butyl)-1,1,3,3-tetramethylguanidine (0.020 mL, 0.097 mmol) in acetonitrile (2 mL), following the procedure described for Example 1. LCMS (2 min, formic) Rt 1.37 min, m/z (ES+) 458 (M+H).
후처리
- customLCMS (2 min, formic) Rt 1.37 min, m/z (ES+) 458 (M+H)
출처 및 근거
- ORD 기록
- ord-3ed7b01455ab436cb4ec550d6e4d9c08
- 출처 데이터셋
- uspto-grants-2016_01
- 특허 번호
- US09242972B2
연결된 노트
불러오는 중…